Clinical Trial Update: The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia [Phase 1]

View source ↗

Summary

Phase 1 safety data on repurposing daratumumab for relapsed or refractory autoimmune antibody-mediated hemolytic anemia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Hemolytic Anemia | Phase 1 | Status: COMPLETED